Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Acadia's Nuplazid May Need Difficult Post-Market Trial, Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Psychopharmacologic Drugs Advisory Committee votes that efficacy and safety were shown, but wants a post-marketing trial, although FDA is unsure how to design it.



Related Companies